IMUX Immunic, Inc.

P/E --
Forward P/E -4.2185407
Price/Sales --
Beta --
Div Yield --
Market Cap --

Company Analysis

Latest News

🟢 Immunic is trading 5.36% up today after Wedbush initiated Outperform coverage

Immunic is trading 5.36% up at $16.89 after Wedbush initiated coverage on August 17, 2026, with an Outperform rating and a $45 price target. - H.C. Wainwright...

Immunic Gains Analyst Confidence with Positive Forecasts and New 'Outperform' Rating

Immunic Gains Analyst Confidence with Positive Forecasts and New 'Outperform' Rating

Immunic, Inc. saw a boost in analyst confidence on Monday. HC Wainwright significantly raised its earnings per share forecasts for the company, now projecting...

🟢 Immunic is trading 5% up today after beating Q2 EPS expectations

Immunic is trading at $16.75, up +5.15%, after investors continued responding to its August 11, 2026, Q2 results and smaller-than-expected loss per share. •...

🟢 Immunic surges 6.5% after Q2 earnings beat estimates and reaffirms year-end Phase 3 data

- Immunic's Q2 report on August 11, 2026, showed a GAAP EPS of -$0.80, beating analyst estimates of -$1.16 by $0.36. - The company reaffirmed that top-line...

🟢 Immunic is trading 5% up today after surpassing second-quarter expectations

Immunic is trading 5.32% up now at $14.85 after reporting second-quarter results that surpassed Wall Street expectations. - Reported an $0.80 loss per share...

Immunic's second quarter 2026 loss per share narrows to $0.80 as Phase 3 trials progress

Immunic's second quarter 2026 loss per share narrows to $0.80 as Phase 3 trials progress

Immunic reported a net loss of $34.1 million for the second quarter of 2026, as the company intensified investments in its late-stage multiple sclerosis...

🟢 Immunic is trading 6.53% up today on renewed biotech M&A optimism

Immunic is trading 6.53% up at $15.49, extending the August 6, 2026 advance as biotech shares rally on renewed merger-and-acquisition optimism. - No fresh...

🟢 Immunic is trading 5.4% up today amid renewed biotech M&A optimism

Immunic is trading 5.4% up at $14.77, with the move driven primarily by a biotech-sector rally. - Biotech ETF XBI is up 2.09% on August 6, 2026, following...

Immunic, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026

Immunic, Inc. (IMUX) is expected to report a consensus EPS of -$1.24 on zero revenue, with the current stock price of $14.05 trading significantly below the...

🟢 Immunic is trading 5.1% up today amid a broad tech rally and cooling inflation data

Immunic is trading 5.1% up at $13.71 as U.S. equities rebound following upbeat tech earnings and favorable economic data. • The broader market is seeing...

🔴 Immunic is trading 5.1% down today on profit-taking following a sector-driven rebound

Immunic is trading 5.1% down at $13.01 as the stock faces profit-taking following yesterday’s biotech-driven rebound. • The decline appears to reflect a shift...

🟢 Immunic is trading 5.2% up today on broad biotech strength and sector rebound

Immunic is trading at $14.08 (+5.15%) on broad biotech strength and a rebound from recent technical pressure. • The stock is tracking a 2.31% rally in the...

🔴 Immunic is trading 5.1% down today amid technical pressure and a cautious market

Immunic is trading 5.1% down at $13.55 today, driven by ongoing downside technical pressure and a cautious broader market sentiment. • The stock has faced...

🔴 Immunic is trading 5% down today amid biotech sector weakness and risk-off sentiment

Immunic is trading 5% down at $14.33 today, July 16, 2026, driven by broader biotech sector weakness and a shift toward risk-off sentiment in growth stocks. •...

🟢 Immunic is trading 5.2% up today on stock-specific strength despite a weak biotech tape

Immunic is trading 5.2% up at $15.40 on stock-specific strength, notably outperforming a broader downturn in the biotechnology sector. • There are no fresh...

🟢 Immunic is trading 6.97% up today in a technical rebound after recent profit-taking

Immunic is trading at $15.80 (6.97% up) in pre-market, staging a technical recovery following a 3.84% decline in the previous session. • The stock is...

🔴 IMUX is trading 5.3% down today on likely profit-taking

IMUX is trading 5.3% down today at $14.55 on likely profit-taking following yesterday’s outperformance versus a weak U.S. market. • No new earnings, clinical...

🟢 IMUX is trading 5% up today despite a lack of fresh catalysts

IMUX is trading 5% up today at $15.61 despite a lack of fresh company-specific catalysts, notably outperforming broadly weaker U.S. indices. • There are no...

🔴 IMUX is trading 5.1% down in pre-market after recent financing-related volatility

IMUX is trading at 5.1% down now at $14.06 in pre-market, extending a pullback after a sharp run-up tied to its large private placement financing and...

Immunic, Inc. Stockholders Approve Addition of 6 Million Shares to Equity Plan

Immunic, Inc. Stockholders Approve Addition of 6 Million Shares to Equity Plan

Immunic, Inc. announced that at its annual meeting of stockholders on June 29, 2026, shareholders approved an amendment to the company's 2019 Omnibus Equity...